通心络胶囊联合前列腺素E1对PCI患者的效果及对内皮功能的影响

Effect of Tongxinluo Capsule combined with prostaglandin E1 on PCI and the endothelial function

目的:探究通心络胶囊联合前列腺素E1对经皮冠状动脉介入治疗(PCI)患者的治疗效果以及对患者内皮功能的影响。方法:选取我院2015年2月~2016年4月收治的PCI患者90例,随机分为两组,对照组应用前列腺素E1治疗,观察组联合应用通心络胶囊治疗,比较两组患者治疗效果及对内皮功能的影响。结果:治疗前两组患者的血液流变学相关指标无明显区别,治疗后均得到一定改善,观察组显著优于对照组;治疗前两组患者的超敏C反应蛋白(hs-CRP)以及白介素6(IL-6)无明显区别,治疗后均得到一定改善,观察组显著低于对照组;治疗前两组患者的血浆一氧化氮(NO)、内皮素-1(ET-1)以及内源性地高辛样因子(EDF)比较无明显区别,治疗后均得到一定改善,观察组显著优于对照组。结论:通心络胶囊联合前列腺素E1的治疗可以改善PCI患者治疗效果,提高患者血管内皮功能。

Objective： To investigate the effect of Tongxinluo Capsule combined with prostaglandin E1 on PCI（ percutaneous coronary intervention）and the endothelial function. Methods： 90 patients with PCI who were treated in our hospital from February 2015 to April 2016 were randomly divided into two groups. The control group was treated with prostaglandin E1. The study group was treated with Tongxinluo Capsule,and therapeutic effects and the effect on endothelial function were compared between two groups. Results： There were no significant differences in hemorheology indexes between two groups before the treatment（ P〈0. 05）. After the treatment,patients in the study group were significantly improved,the effect in the study group was significantly better than that in the control group（ P〈0. 05）; There were no significant differences in levels of hs-CRP and IL-6 between two groups before the treatment（ P〈0. 05）. There was no significant difference in NO,ET-1 and EDF between the two groups before the treatment（ P〈0. 05）,and those indicators in the treatment group were significantly improved compared with the control group（ P〈0. 05）. Conclusion： Tongxinluo Capsule combined with prostaglandin E1 can improve the treatment effect of PCI patients and improve the vascular endothelial function.